These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17430241)

  • 1. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.
    Landreth G
    Curr Alzheimer Res; 2007 Apr; 4(2):159-64. PubMed ID: 17430241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alzheimer's disease].
    Hanyu H; Sato T
    Nihon Rinsho; 2010 Feb; 68(2):330-4. PubMed ID: 20158105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
    Landreth G; Jiang Q; Mandrekar S; Heneka M
    Neurotherapeutics; 2008 Jul; 5(3):481-9. PubMed ID: 18625459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.
    Jiang Q; Heneka M; Landreth GE
    CNS Drugs; 2008; 22(1):1-14. PubMed ID: 18072811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents.
    Kaundal RK; Sharma SS
    Drug News Perspect; 2010 May; 23(4):241-56. PubMed ID: 20520853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARgamma as a therapeutic target in central nervous system diseases.
    Sundararajan S; Jiang Q; Heneka M; Landreth G
    Neurochem Int; 2006 Jul; 49(2):136-44. PubMed ID: 16766086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
    Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
    Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
    Cheng H; Shang Y; Jiang L; Shi TL; Wang L
    Int J Neurosci; 2016; 126(4):299-307. PubMed ID: 26001206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bis(ethylmaltolato)oxidovanadium (IV) alleviates neuronal apoptosis through regulating peroxisome proliferator-activated receptor γ in a triple transgenic animal model of Alzheimer's disease.
    He Z; Song J; Li X; Li X; Zhu H; Wu C; Xiao W; Du X; Ni J; Li N; Liu Q
    J Biol Inorg Chem; 2021 Aug; 26(5):551-568. PubMed ID: 34240269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.
    Heneka MT; Landreth GE; Hüll M
    Nat Clin Pract Neurol; 2007 Sep; 3(9):496-504. PubMed ID: 17805244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.
    Hsu WJ; Wildburger NC; Haidacher SJ; Nenov MN; Folorunso O; Singh AK; Chesson BC; Franklin WF; Cortez I; Sadygov RG; Dineley KT; Rudra JS; Taglialatela G; Lichti CF; Denner L; Laezza F
    Exp Neurol; 2017 Sep; 295():1-17. PubMed ID: 28522250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1.
    Wang X; Wang Y; Hu JP; Yu S; Li BK; Cui Y; Ren L; Zhang LD
    Mol Neurobiol; 2017 May; 54(4):2939-2949. PubMed ID: 27023226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease.
    Feinstein DL
    Diabetes Technol Ther; 2003; 5(1):67-73. PubMed ID: 12725709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone rescues human neural stem cells from amyloid-beta induced ER stress via PPARγ dependent signaling.
    Lin CH; Nicol CJB; Cheng YC; Chen SJ; Yen CH; Huang RN; Chiang MC
    Exp Cell Res; 2018 Sep; 370(2):312-321. PubMed ID: 29964054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
    Belvisi MG; Hele DJ; Birrell MA
    Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease.
    Landreth GE; Heneka MT
    Neurobiol Aging; 2001; 22(6):937-44. PubMed ID: 11755002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease.
    Landreth G
    Exp Neurol; 2006 Jun; 199(2):245-8. PubMed ID: 16733054
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosiglitazone activation of PPARγ-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction and oxidative stress.
    Chiang MC; Nicol CJ; Cheng YC; Lin KH; Yen CH; Lin CH
    Neurobiol Aging; 2016 Apr; 40():181-190. PubMed ID: 26973118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.